Moving with the Power of the Patient

Physical activity has been shown to have beneficial effects on mood, muscle efficacy, fatigue, quality of life, independence and longevity for everyone including the 80 million U.S. citizens who are suffering from a metabolic disease. But only a small percentage get enough exercise to reap these benefits. iMETx products help individuals be more physically active in a way that enables easy adoption into the current lifestyle and sustainable for lifelong behavior change.

Clinical Research – Breakthrough Results

Physical activity is important for all people, but especially for the chronically ill or highly deconditioned, including patients going through chemotherapy or hormone treatment.

Initial clinical trials with iMETx products were conducted with breast cancer patients and survivors, adding further evidence that inactivity has harmful effects that could hinder patients’ ability to heal.

The first clinical study with newly diagnosed breast cancer patients at the Indiana University Melvin and Bren Simon Cancer Center found that with chemo and hormone therapies patients experienced:

  • A 25% reduction in their ability to produce energy, which inhibits the production of protective antibodies
  • Diminished quality of life, including fatigue and adverse cognitive side effects.

The follow-up iMETx Therapy clinical study recently completed with breast cancer survivors demonstrated statistically significant results. The most highly deconditioned segment showed the greatest response: a 46% improvement in energetic capacity after only 12 weeks of iMETx Therapy. An abstract will be published at the annual American Society of Clinical Oncology (ASCO) meeting in June 2019.

 “Similar to precision-based medicine in cancer therapeutics, we expect the iMETx dynamic individualized interventions to be more effective than current low compliance population-based guidelines. The methods and techniques emerging from these studies should have broad applicability to other chronic metabolic diseases and general health.” Tarah Ballinger, MD, Assistant Professor of Clinical Medicine Division of Hematology Oncology, Indiana School of Medicine 

Research Grant Supporters

  • Breast Cancer Research Foundation ($400,000)
  • Susan G. Komen Foundation ($1 million)
  • Indiana University Melvin and Bren Simon Cancer Center

What the Experts are Saying

iMETx has the right strategy, external research support and management team to fully realize the potential of this breakthrough advance in personalized movement therapy to help improve patient lives.